Other Liver Disease
Other Infections
AASLD 2017: Women with Fatty Liver Disease at Higher Risk for Heart Disease
- Details
- Category: Steatosis/NAFLD/NASH
- Published on Wednesday, 13 December 2017 00:00
- Written by Liz Highleyman
Women with non-alcoholic fatty liver disease (NAFLD) had a higher risk of cardiovascular events including chest pain and heart failure compared to women without the condition -- and about the same risk as men with NAFLD -- in a study presented at the 2017 AASLD Liver Meeting in October in Washington, DC.
AASLD 2017: Experimental NASH Therapy Improves Liver Fat and Fibrosis
- Details
- Category: Steatosis/NAFLD/NASH
- Published on Wednesday, 01 November 2017 00:00
- Written by Liz Highleyman
GS-0976, an acetyl-CoA carboxylase (ACC) inhibitor being developed by Gilead Sciences, led to significant reductions in liver fat accumulation and fibrosis in people with non-alcoholic steatohepatitis (NASH), according to Phase 2 study results presented at the 2017 AASLD Liver Meeting last week in Washington, DC.
EASL 2016: Emricasan May Improve Inflammation and Liver Function in People with Cirrhosis
- Details
- Category: Other Liver Disease
- Published on Friday, 22 April 2016 00:00
- Written by Liz Highleyman
The novel caspase inhibitor emricasan (IDN-6556) led to improvements in various biomarkers and decreases in MELD scores in patients with liver cirrhosis due to hepatitis C, heavy alcohol use, or other causes, which significant declines among those who started with worse liver dysfunction, according to a late-breaking presentation at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) last week in Barcelona.
Cenicriviroc May Reduce Fibrosis in People with Fatty Liver Disease
- Details
- Category: Steatosis/NAFLD/NASH
- Published on Thursday, 12 October 2017 00:00
- Written by Liz Highleyman
Cenicriviroc, a drug that blocks both CCR5 and CCR2 receptors on immune cells, was associated with a decrease in liver fibrosis in people with non-alcoholic steatosis, a type of fatty liver disease, according to a report in the August 17 online edition of Hepatology.
EASL 2016: NorUrsodeoxycholic Acid Help Rare Bile Duct Disease with No Current Treatment
- Details
- Category: Other Liver Disease
- Published on Tuesday, 19 April 2016 00:00
- Written by Liz Highleyman
A Phase 2 European trial showed that norUrsodeoxycholic acid leads to a significant reduction in serum alkaline phosphatase in people with primary sclerosing cholangitis (PSC), a rare but serious bile duct disease, according to a report presented at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) last week in Barcelona.
EASL 2017: Norfloxacin Reduces Risk of Death for People with Decompensated Cirrhosis
- Details
- Category: Liver Decompensation
- Published on Saturday, 22 April 2017 00:00
- Written by Keith Alcorn
Long-term prophylaxis with the antibiotic norfloxacin significantly reduced the incidence of death in people with decompensated cirrhosis over a 6-month follow-up period, according to a French randomized trial reported at the EASL International Liver Congress this week in Amsterdam.
EASL 2015: Milk Thistle May Improve Steatohepatitis, Capsaicin from Chili Peppers Helps Fibrosis
- Details
- Category: Steatosis/NAFLD/NASH
- Published on Wednesday, 13 May 2015 00:00
- Written by Liz Highleyman
People who used silymarin, derived from the milk thistle plant, experienced a resolution of non-alcoholic steatohepatitis (NASH) and a reduction in liver fibrosis in a randomized, placebo-controlled trial, researchers reported at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna. Another study found that dietary capsaicin, derived from chili peppers, was associated with improvement in mice with artificially induced fibrosis, the precursor to cirrhosis.
AASLD 2016: When You Eat May Contribute to Fatty Liver Disease as Much as What You Eat
- Details
- Category: Steatosis/NAFLD/NASH
- Published on Monday, 14 November 2016 00:00
- Written by Liz Highleyman
People who skip breakfast and eat late at night may have an elevated risk of non-alcoholic fatty liver disease (NAFLD), according to research presented at the AASLD Liver Meeting this week in Boston. This suggests that meal timing and frequency of meals may be modifiable risk factors for fatty liver disease, which can lead to cirrhosis and liver cancer.
EASL 2015: Heavy Drinkers Contribute Most to Liver Cirrhosis Burden; Heavy Alcohol Use Rising in U.S.
- Details
- Category: Other Liver Disease
- Published on Tuesday, 12 May 2015 00:00
- Written by Liz Highleyman
The number of people who regularly consume more than a moderate amount of alcohol is a better indicator of alcoholic cirrhosis prevalence than per capita annual consumption, or the total amount consumed per year divided by the entire population, according to a presentation at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna. A related study found that heavy drinking and binge drinking have risen over the past decade in the U.S., largely due to increases among women.
More Articles...
- Coffee Helps Protect Against Liver Cancer, Obesity Confirmed as Risk Factors
- Ezetimibe Did Not Reduce Liver Fat in NASH Trial, New Therapies Under Study
- Hospitalizations Due to Hepatitis A Declining in the U.S., CDC Study Finds
- Coffee Linked to Reduced Liver Inflammation, Lower Liver Cancer Risk
- Everolimus Did Not Improve Survival for Advanced Liver Cancer Patients
- DDW 2014 and EASL 2014: Rifaximin May Be Beneficial for People with Advanced Liver Cirrhosis
- EASL 2014: Obeticholic Acid Looks Promising for Primary Biliary Cirrhosis, May Improve Gut Health
- EASL 2014: New Research Sheds Light on Liver Cancer Diagnosis, Staging, and Treatment
- EASL 2014: Fatty Liver Disease Is a Risk Factor for Heart Disease and Diabetes
- Researchers Transform Mouse Skin Cells Into Functional Liver Cells
- FDA: Discontinue Higher-dose Acetaminophen Combo Pills
- AASLD 2013: Label Warnings, Counseling Do Not Eliminate Risk of Acetaminophen Toxicity
- Hepatitis E Uncommon among HIV+ People, but May Cause Unexplained Liver Enzyme Elevations
- Ribavirin May Be Effective against Acute Hepatitis E
- Hepatitis A Vaccine Response Durable in People with HIV
- HIV Positive People May Need Triple Dose of Hepatitis A Vaccine
- DDW 2009: Strategies for Managing Acetaminophen-related Liver Disease and Acute Liver Failure
- FDA Will Require Additional Warnings for Over-the-Counter Painkillers, Including Acetaminophen, Aspirin, and Ibuprofen
Web Design and Development by